Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of pancreatic cancer
3.2.1.2 Advancements in diagnostic technologies
3.2.1.3 Growing healthcare expenditure globally
3.2.1.4 Rising awareness regarding early cancer detection
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulatory scenarios
3.2.2.2 High cost of diagnostic tests
3.3 Growth potential analysis
3.4 Reimbursement scenario
3.5 Regulatory landscape
3.6 Technological landscape
3.6.1 Core technologies
3.6.2 Adjacent technologies
3.7 Pricing analysis, 2023
3.7.1 By region
3.7.2 By key player
3.8 Future market trends
3.9 Porter’s analysis
3.10 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Instruments
5.3 Consumables
Chapter 6 Market Estimates and Forecast, By Test Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Imaging test
6.2.1 CT scan
6.2.2 MRI
6.2.3 Ultrasound
6.2.4 PET
6.2.5 Other imaging tests
6.3 Biopsy
6.4 Blood test
6.4.1 Liver function tests
6.4.2 Tumor markers
6.4.3 Other blood tests
6.5 Other test types
Chapter 7 Market Estimates and Forecast, By Cancer Type, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Exocrine
7.2.1 Adenocarcinoma
7.2.2 Squamous cell carcinoma
7.2.3 Adenosquamous carcinoma
7.2.4 Colloid carcinoma
7.3 Endocrine
Chapter 8 Market Estimates and Forecast, By End-use, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospitals and clinics
8.3 Diagnostic laboratories
8.4 Diagnostic imaging centers
8.5 Cancer research institutes
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Abbott Laboratories
10.2 Agilent Technologies, Inc.
10.3 ASURAGEN, INC.
10.4 Becton, Dickinson and Company
10.5 BioMarker Strategies
10.6 Canon Inc.
10.7 Danaher Corporation
10.8 F. Hoffmann-La Roche Ltd.
10.9 GE HealthCare Technologies Inc.
10.10 Hitachi, Ltd.
10.11 Illumina, Inc.
10.12 Koninklijke Philips N.V.
10.13 Myriad Genetics, Inc.
10.14 Prestige Biopharma Limited (PBP)
10.15 QIAGEN N.V.
10.16 Siemens Healthineers AG
10.17 Sysmex Corporation
10.18 Thermo Fisher Scientific Inc.
